Document text
Principal Investigator: Adrian McDermott
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $2,371,299
Funding agency: National Institute of Allergy and Infectious Diseases
In March 2020 the VIP began working in collaboration with VRC laboratories on the trial readouts for the Phase 1 DIMID 20-003 trial. Later that year the VIP was working within the Operation Warp Speed (OWS) (now called Countermeasures Accelerations Group) testing USG identified CoVID-19 vaccines. The VIP's original focus was on the standard ELISA automated assay developing the readout for the SARS COV-2 S2P, RBD and N proteins. Pseudovirus neutralization was included with Dr. Graham (VRC) and David Montefiori (Duke). Increased concentration on MSD ECLIA development led to single-plex and 4-plex assay development, for higher throughput inclusive of qualification to phase 3 clinical trial validation with standardized documentation and implementation of protocols. These assays were deployed by the VIP for OWS correlates of protection analyses. VIP Phase I testing support led to the development of a comprehensive workflow to follow full sample chain of custody from reception to results reporting/upload. Audit for Phase I and Phase III support determined the improved QMS, Equipment capacity, expanded instrumentation and personnel, sample traceability with data transfer plan, Technology transfer and FDA Drug master Files. The VIP tested approximately 30,000 samples that were uploaded for correlates of protection and immunogenicity studies.
In addition, the VIP investigated basic B and T cell immunobiology to elucidated the mechanisms that drive the SARS CoV-2 transmission and to inform the improved development of second generation variant vaccines and third dose. VIP will continue to develop sophisticated analyses that supports in-depth investigation of SARS CoV 2 through sero-surveillance multi investigator collaborative studies, clinical vaccine trials, including highly qualified clinical assays for use in IND submissions and product licensure purposes. This template of advanced serological and cellular analyses for emerging pathogens will be extended for Vaccine Preparedness efforts at the VRC and NIAID in general.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Acceleration><Assay><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Bioassay><Biologic Assays><Biological Assay><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 transmission><COVID-19 vaccine><COVID-19 virus><COVID-19 virus transmission><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinical><CoV-2><CoV2><Collaborations><Coronaviridae><Coronavirus><Development><Documentation><Dose><Drugs><ELISA><Emerging Communicable Diseases><Emerging Infectious Diseases><Enzyme-Linked Immunosorbent Assay><Equipment><Generations><Goals><Human Resources><Immunobiology><Immunology><Immunophysiology><Investigation><Investigators><Laboratories><Licensure><Manpower><Medication><NIAID><National Institute of Allergy and Infectious Disease><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Phase 3 Clinical Trials><Phase III Clinical Trials><Preparedness><Proteins><Protocol><Protocols documentation><Public Health><Readiness><Reporting><Research><Research Personnel><Researchers><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 transmission><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serology><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Speed><Standardization><T-Cells><T-Lymphocyte><Technology Transfer><Testing><Vaccine Clinical Trial><Vaccines><Validation><Variant><Variation><Wuhan coronavirus><assay development><clinical investigation><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 transmission><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><data exchange><data transfer><data transmission><develop a vaccine><development of a vaccine><developmental><drug/agent><emerging pathogen><hCoV19><immunogenicity><improved><instrumentation><interest><nCoV2><new pathogen><novel pathogen><operation><personnel><phase 1 evaluation><phase 1 testing><phase I evaluation><phase I testing><phase III protocol><programs><serology surveillance><serosurveillance><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 transmission><thymus derived lymphocyte><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine development><vaccine for novel coronavirus><vaccine formulation>